BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2025
BIOQUAL (BIOQ) has reported its unaudited financial results for the second quarter of fiscal year 2025, showing significant declines across key metrics. Revenue decreased to $23.17 million for the six months ended November 30, 2024, down from $31.45 million in the same period of 2023. The company reported a net loss of $1.89 million for the six-month period, compared to a net income of $1.38 million in the previous year.
For the three-month period ended November 30, 2024, revenue was $11.40 million, down from $15.87 million, with a net loss of $1.21 million compared to a net income of $484,661 in the prior year. Basic and diluted earnings per share declined to ($2.11) for the six-month period, compared to $1.55 in 2023.
BIOQUAL (BIOQ) ha riportato i suoi risultati finanziari non auditati per il secondo trimestre dell'anno fiscale 2025, evidenziando significative riduzioni in vari indicatori chiave. I ricavi sono diminuiti a $23,17 milioni per i sei mesi terminati il 30 novembre 2024, rispetto ai $31,45 milioni nello stesso periodo del 2023. L'azienda ha registrato una perdita netta di $1,89 milioni per il periodo di sei mesi, rispetto a un utile netto di $1,38 milioni nell'anno precedente.
Per il periodo di tre mesi terminato il 30 novembre 2024, i ricavi sono stati di $11,40 milioni, in diminuzione rispetto ai $15,87 milioni, con una perdita netta di $1,21 milioni rispetto a un utile netto di $484.661 nell'anno precedente. Gli utili per azione, sia base che diluiti, sono scesi a ($2,11) per il periodo di sei mesi, rispetto a $1,55 nel 2023.
BIOQUAL (BIOQ) ha reportado sus resultados financieros no auditados para el segundo trimestre del año fiscal 2025, mostrando importantes disminuciones en métricas clave. Los ingresos cayeron a $23.17 millones para los seis meses finalizados el 30 de noviembre de 2024, desde $31.45 millones en el mismo período de 2023. La compañía reportó una pérdida neta de $1.89 millones para el período de seis meses, en comparación con una ganancia neta de $1.38 millones el año anterior.
Para el período de tres meses terminado el 30 de noviembre de 2024, los ingresos fueron de $11.40 millones, bajando desde $15.87 millones, con una pérdida neta de $1.21 millones en comparación con una ganancia neta de $484,661 en el año anterior. Las ganancias por acción básicas y diluidas cayeron a ($2.11) para el período de seis meses, en comparación con $1.55 en 2023.
BIOQUAL (BIOQ)는 2025 회계연도 2분기의 감사되지 않은 재무 결과를 발표했으며, 주요 지표에서 상당한 하락을 보였습니다. 2024년 11월 30일 기준으로 종료된 6개월 동안의 수익은 $23.17 백만으로, 2023년 같은 기간의 $31.45 백만에서 감소했습니다. 이 회사는 6개월 기간 동안 $1.89 백만의 순손실을 보고했으며, 이는 지난해의 $1.38 백만 순이익에 비해 감소한 것입니다.
2024년 11월 30일 기준으로 종료된 3개월 기간 동안 수익은 $11.40 백만으로, $15.87 백만에서 감소하였고, 순손실은 $1.21 백만으로, 지난해의 $484,661 순이익과 비교되었습니다. 기본 및 희석 주당 순이익은 6개월 기간 동안 ($2.11)로 감소하여, 2023년의 $1.55에 비해 하락했습니다.
BIOQUAL (BIOQ) a publié ses résultats financiers non vérifiés pour le deuxième trimestre de l'exercice 2025, montrant des baisses significatives dans plusieurs indicateurs clés. Le chiffre d'affaires a diminué à $23,17 millions pour les six mois se terminant le 30 novembre 2024, contre $31,45 millions au cours de la même période en 2023. L'entreprise a enregistré une perte nette de $1,89 millions pour la période de six mois, par rapport à un bénéfice net de $1,38 millions l'année précédente.
Pour la période de trois mois se terminant le 30 novembre 2024, le chiffre d'affaires était de $11,40 millions, en baisse par rapport à $15,87 millions, avec une perte nette de $1,21 millions comparée à un bénéfice net de $484,661 l'année précédente. Le résultat de base et dilué par action a chuté à ($2,11) pour la période de six mois, contre $1,55 en 2023.
BIOQUAL (BIOQ) hat seine ungeprüften finanziellen Ergebnisse für das zweite Quartal des Geschäftsjahres 2025 veröffentlicht, die erhebliche Rückgänge in Schlüsselkennzahlen zeigen. Der Umsatz fiel auf $23,17 Millionen für die sechs Monate bis zum 30. November 2024, verglichen mit $31,45 Millionen im gleichen Zeitraum 2023. Das Unternehmen berichtete von einem Nettoverlust von $1,89 Millionen für den sechsmonatigen Zeitraum, im Vergleich zu einem Nettogewinn von $1,38 Millionen im Vorjahr.
Für den Zeitraum von drei Monaten bis zum 30. November 2024 betrug der Umsatz $11,40 Millionen, ein Rückgang von $15,87 Millionen, wobei ein Nettoverlust von $1,21 Millionen im Vergleich zu einem Nettogewinn von $484.661 im Vorjahr verzeichnet wurde. Das Ergebnis je Aktie, sowohl basic als auch diluted, fiel für den sechsmonatigen Zeitraum auf ($2,11), im Vergleich zu $1,55 im Jahr 2023.
- None.
- Revenue declined 26.3% to $23.17M for six months ended November 30, 2024
- Shifted from $1.91M profit to $2.60M loss before income tax (six months)
- Net income turned to $1.89M loss from $1.38M profit year-over-year
- EPS decreased significantly from $1.55 to ($2.11)
- Q2 revenue dropped 28.2% to $11.40M
Six Months Ended |
|
Three Months Ended |
|||||||||||||
November 30, |
|
November 30, |
|||||||||||||
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
|
Revenue |
$ |
23,165,920 |
|
$ |
31,448,326 |
$ |
11,395,438 |
|
$ |
15,869,404 |
|||||
(Loss) Income Before Income Tax |
$ |
(2,604,227 |
) |
$ |
1,909,744 |
|
$ |
(1,672,402 |
) |
$ |
668,561 |
|
|||
Net (Loss) Income |
$ |
(1,887,527 |
) |
$ |
1,384,144 |
|
$ |
(1,212,202 |
) |
$ |
484,661 |
|
|||
Basic Earnings per Share |
|||||||||||||||
of Common Stock |
$ |
(2.11 |
) |
$ |
1.55 |
|
$ |
(1.36 |
) |
$ |
0.54 |
|
|||
Diluted Earnings per Share |
|||||||||||||||
of Common Stock |
$ |
(2.11 |
) |
$ |
1.55 |
|
$ |
(1.36 |
) |
$ |
0.54 |
|
|||
Weighted Average |
|||||||||||||||
Number of Shares Outstanding |
|
|
|||||||||||||
For Basic Earnings Per Share |
|
894,416 |
|
|
894,416 |
|
|
894,416 |
|
|
894,416 |
|
|||
Weighted Average |
|||||||||||||||
Number of Shares Outstanding |
|||||||||||||||
For Diluted Earnings Per Share |
|
894,399 |
|
|
894,398 |
|
|
894,394 |
|
|
894,390 |
|
|||
For more detail related to the fiscal year 2025 unaudited second quarter results, please visit our web site at www.bioqual.com.
|
|||||||||||||||
Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government and commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250121790095/en/
Mark G. Lewis, Ph.D., CEO (240-404-7654)
Source: BIOQUAL, Inc.
FAQ
What was BIOQ's revenue for Q2 FY2025?
How much did BIOQ's net income decline in Q2 FY2025?
What was BIOQ's earnings per share for the first six months of FY2025?
How much revenue did BIOQ generate in the first six months of FY2025?
